The effect of vitamin E, probucol, and lovastatin on oxidative status and aortic fatty lesions in hyperlipidemic-diabetic hamsters

Atherosclerosis

Volumn 149, Issue 2, 2000, Pages 277-286

  El Swefy, S ^a   Schaefer, E J ^a   Seman, L J ^a,b   Van Dongen, D ^a   Sevanian, A ^c   Smith, D E ^a   Ordovas, J M ^a   El Sweidy, M ^d   Meydani, M ^a  

^a TUFTS UNIVERSITY   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d Zagazig University   (Egypt)

Author keywords

Cholesterol oxide; Fatty streak, Antioxidant; Foam cell; Hamster

Indexed keywords

ALPHA TOCOPHEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID PEROXIDE; METAFANE; MEVINOLIN; PHOSPHOLIPID; PROBUCOL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; AORTA WALL; ARTICLE; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; FOAM CELL; GLUCOSE BLOOD LEVEL; HAMSTER; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; STREPTOZOCIN DIABETES;

ANIMALS; ANIMALS, NEWBORN; ANTICHOLESTEREMIC AGENTS; ANTIOXIDANTS; ARTERIOSCLEROSIS; CELLS, CULTURED; CRICETINAE; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; FOAM CELLS; HYPERLIPIDEMIAS; LIPID PEROXIDATION; LOVASTATIN; MALE; MESOCRICETUS; PROBUCOL; REFERENCE VALUES; STREPTOZOCIN; VITAMIN E;

EID: 0034099364     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00331-7     Document Type: Article

References (53)

1. Uusitupa M.U., Niskanen L.K., Siitonen O. 5-Year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level and abnormalities in lipoprotein composition in non insulin-dependent diabetic and non diabetic subjects. Circulation. 82:1990;27-36.
2. Expert Panel. Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. 1993.
3. Reaven P. Dietary and pharmacological regimens to reduce lipid peroxidation in non insulin-dependent diabetes mellitus. Am. J. Clin. Nutr. 62:1995;1483s-1489s.
4. Tilly-Kiesi M., Syvanne M., Kuusi T., Lahdenpera S., Taskinen M.R. Abnormalities in normolipidemic type II diabetic and non diabetic patients with coronary artery disease. J. Lipid Res. 33:1992;333-342.
5. Siegel R.D., Cupples A., Schaefer E., Wilson P.W.F. Lipoproteins, apolipoproteins, and low-density lipoprotein size among diabetics in the Framingham Offspring study. Metabolism. 45:1996;1267-1272.
6. Witztum J.L., Steinberg D. Role of oxidized low density lipoprotein in atheriosclerosis. J. Clin. Invest. 881:1991;1785-1792.
7. Morel D.W., Hessler J.R., Chisolm G.M. Low density lipoprotein cytotoxicity induced by free radical peroxidation of lipid. J. Lipid Res. 24:1983;1070-1076.
8. Cybulski M.L., Glmbrone M.A. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science. 251:1990;788-791.
9. Jacobs M., Plane F., Bruckdorfer K.R. Native and oxidized low density lipoproteins have different inhibitor effects on endothelium-derived relaxing factor in rabbit aorta. Br. J. Pharmacol. 100:1990;21-26.
10. Armstrong D., Al-Awadi F. Lipid peroxidation and retinopathy in streptozotocin-induced diabetes. Free Rad Biol Med. 11:1991;433-436.
11. Jain S.K., Mc Vie R., Duett J., Herbst J.J. Erythrocyte membrane lipid peroxidation and glycosylated hemoglobin in diabetes. Diabetes. 38:1989;1539-1543.
12. Rabini R.A., Fumelli P., Galassi R., Dousset N., Taus M., Ferretti G., Mazzanti L., Curatola G., Solera M.L., Valdiguie P. Increased susceptibility to lipid oxidation of low-density lipoproteins and erythrocyte membranes from diabetic patients. Metab. Clin. Exp. 43:1994;1470-1474.
13. Kobayashi K., Watanabe J., Umeda F., Nawata H. Glycation accelerates the oxidation of low density lipoprotein by copper ions. Endocrin. J. 42:1995;461-465.
14. Napoli C., Triggiani M., Palumbo G., Condorelli M., Chiariello M., Ambrosio G. Glycosylation enhances oxygen radical-induced modifications and decreases acetylhydrolase activity of human low density lipoprotein. Basic Res. Cardiol. 92:1997;96-105.
15. Li D., Devaraj S., Fuller C., Bucala R., Jialal I. Effect of alpha-tocopherol on LDL oxidation and glycation: in vitro and in vivo studies. J. Lipid Res. 39:1996;1978-1986.
16. Fuller C.J., Chandalia M., Garg A., Grundy S.M., Jialal I. RRR-alpha-tocopheryl acetate supplementation at pharmacologic doses decreases low-density-lipoprotein oxidative susceptibility but not protein glycation in patients with diabetes mellitus. J. Clin. Nutr. 63:1996;753-759.
17. Chisolm G.M., Morel D.W. Lipoprotein oxidation and cytotoxicity: effect of probucol on streptozotocin treated rats. Am. J. Cardiol. 62:1983;20B-26B.
18. Cameron N.E., Cotteer M.A., Archibald V., Dines K.C., Maxfield E.K. Antioxidant and pro-oxidant effects on nerve conduction velocity, enoneurial blood flow and oxygen tension in non diabetic and Streptizocin-diabetic rats. Diabetologia. 37:1994;449-459.
19. Andersen J.M., Cook L.R. Regulation of gallbladder cholesterol concentration in the hamster. Role of hepatic cholesterol level. Biochem. Biophys. Acta. 875:1986;582-592.
20. Spady D.K., Dietschy J.M. Interaction of dietary cholesterol and triglycerides in the regulation of hepatic low density lipoprotein transport in the hamster. J. Clin. Invest. 81:1988;300-309.
21. Nistor A., Bulla A., Fillip D.A., Radu A. The hyperlipidemic hamsters as a model of experimental atherosclerosis. Atherosclerosis. 68:1987;159-173.
22. Arbeeny C.M., Meyers D.S., Berquist K.E., Gregg R.E. Inhibition of fatty acid synthesis decreases very low density lipoprotein secretion in the hamster. J. Lipid Res. 33:1992;843-851.
23. Ebara T., Hirano T., Mamo J.C.L., Sakamaki R., Furukawa S., Nagano S., Takahashi T. Hyperlipidemia in streptozocin-Diabetic hamsters as a model for human Insulin-Deficient diabetes: Comparison to streptozocin-Diabetic rats. Metabolism. 43:1994;299-305.
24. Povoski S.P., McCullough P.J., Zhou W., Bell R.H. Induction of diabetes mellitus in Syrian Golden Hamsters using stored equilibrium solutions of streptozotocin. Lab. Animal Sci. 43:1993;310-313.
25. Otto J., Ordovas J.M., Smith D., Dongen D.V., Nicolosi R.J., Schaefer E.J. Lovastatin inhibits diet induced atherosclerosis in FIB golden syrian hamsters. Atherosclerosis. 114:1995;19-28.
26. McNamara J.R., Schaefer E.J. Automated enzymatic standardized lipid analyses for plasma and apolipoprotein fractions. Clin. Chem. Acta. 166:1987;1-8.
27. Neeley W.E. Simple automated determination of serum or plasma glucose by a hexokinase-glucose-6-phosphate dehydrogenase method. Clin. Chem. 18:1972;509-515.
28. Takayama M., Itoh S., Nagasaki T., Tanimizu I. A new enzymatic method for determination of serum choline-containing phospholipids. Clin. Chem. Acta. 79:1977;93-98.
29. Meydani M., Chon J.S., Macauley J.B., McNamara J.R., Blumberg J.B., Schaefer E.J. Postprandial changes in the plasma concentration of α- and γ- tocopherol in human subjects fed fat rich meal supplemented with fat-soluble vitamins. J. Nutr. 119:1989;1252-1258.
30. Sevanian A., Seraglia R., Traldi P., Rossato P., Ursini F., Hodis H.N. Analytical approaches to the measurement of plasma cholesterol oxidation products using gas- and high-performance liquid chromatography/mass spectrometry. Free. Rad. Biol. Med. 17:1994;397-410.
31. Jialal I., Vega G.L., Grundy S.M. Physiological levels of ascorbate inhibit the oxidative modification of LDL. Atherosclerosis. 82:1990;185-191.
32. Jialal I., Scaccini C. Antioxidants and atherosclerosis. Curr. Opin. Lipidol. 3:1992;324-328.
33. Bellomo G., Maggi E., Poli M., Agosta F.G., Bollati P., Finardi G. Autoantibodies against oxidatively modified low-density lipoproteins in NIDDM. Diabetes. 44:1995;60-66.
34. Maxwell S.R., Thomason H., Sandler D., Leguen C., Baxter M.A., Thorpe G., Jones A.F., Barnett A.H. Antioxidant status in patients with uncomplicated insulin-dependent and non-insulin-dependent diabetes mellitus. Eur. J. Clin. Invest. 27:1997;484-490.
35. The Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practised in the diabetes control and complications trial, J Am Med Assoc 1996;276:1409-1415.
36. Ceriello A., Guigliano D., Quatraro A., Donzella A., Dipolo G., Lefebvre P. Vitamin E reduction of protein glycosylation in diabetes: new prospect for prevention of diabetic complications. Diabet. Care. 14:1991;68-72.
37. Arad Y., Ramakrishnan R., Ginsberg H.N. Effects of lovastatin therapy on very low density lipoprotein Triglyceride metabolism in subjects with combined hyperlipidemia: Evidence of reduced assembly and secretion of Triglyceride-rich lipoproteins. Metabolism. 41:1992;487-493.
38. Chen L., Haught W.H., Yang B., Saldeen T.G., Parathasarathy S., Mehta J.L. Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. J. Am. Coll. Cardiol. 30:1997;569-575.
39. Singh R.B., Singh N.K., Rastogi S.S., Wander G.S., Aslam M., Onouchi Z., Kummerow F.A., Nangia S. Antioxidant effects of lovastatin and vitamin E on experimental atherosclerosis in rabbits. Cardiovascul. Drug. Therap. 11:1997;575-580.
40. Hussein H., Schlezinger S., Rosenblat M., Keidar S., Aviram M. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Atherosclerosis. 128:1997;1-18.
41. Stampfer M.J., Hennekens C.H., Manson J.E., Colditz G.A., Rosner B., Willett W.C. Vitamin E consumption and the risk of coronary disease in women. New Engl. J. Med. 328:1993;1444-1449.
42. Rimm E.B., Stampfer M.J., Ascherio A., Giovannucci E., Colditz G.A., Willett W.C. Vitamin E consumption and the risk of coronary heart disease in men. New Engl. J. Med. 328:1993;1450-1456.
43. Jialal I., Fuller C.J., Huet B.A. The effect of α-tocopherol supplementation on LDL oxidation: a dose-response study. Arterioscler. Thromb. Vasc. Biol. 15:1995;190-198.
44. Munday J.S., Thompson K.G., Manktelo B.W. Dietary antioxidants do not reduce fatty streak formation in the C%&BL/6 mouse atherosclerosis model. Artherioscl. Thromb. Vas. Biol. 18:1998;114-119.
45. Tada H., Oida K., Kutsumi Y., Shimada Y., Nakai T., Miyabo S. Effects of probucol on impaired cardiac performance and lipid metabolism in streptozotocin-induced diabetic rats. Cardiovasc. Pharmacol. 20:1992;179-186.
46. Buckley M.M., Goa K.L., Price A.H., Brogden R.N. Probucol: A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolemia. Drugs. 37:1989;761-800.
47. Nagano Y., Nakamura T., Matsuzawa Y., Cho M., Ueda Y., Kita T. Probucol and atherosclerosis in the Watanabe heritable hyperlipidemic rabbit: Long term antiatherogenic effect and effects on established plaques. Atherosclerosis. 92:1992;131-140.
48. Regstrom J., Walldius G., Carlson L.A., Nilsson J. Effect of probucol treatment on the susceptibility of low density lipoprotein isolated from hypercholesterolemic patients to become oxidatively modified in vitro. Atherosclerosis. 82:1990;43-51.
49. Steinberg D., Parthasarathy S., Carew T.E. In vivo inhibition of foam cell development by probucol in Watanabe rabbits. Am. J. Cardiol. 62:1988;6B-12B.
50. Cader A.A., Steinberg F.M., Mazzone T., Chait A. Mechanisms of enhanced macrophage apoE secretion by oxidized LDL. J. Lipid Res. 38:1997;981-991.
51. Patel R.P., Diczfalusy U., Dzeletovic S., Wilson M.T., Darley-Usmar V.M. Formation of oxysterols during oxidation of low density lipoprotein by peroxynitrite, myoglobin, and copper. J. Lipid Res. 37:1996;2361-2371.
52. Morin R.J., Peng S.-K. The role of cholesterol oxidation products in the pathogenesis of atherosclerosis. Ann. Clin. Lab. Sci. 19:1989;225-237.
53. Fruebis J., Bird D.A., Pattison J., Palinski W. Extent of antioxidant protection of plasma LDL is not a predictor of the antiatherogenic effect of antioxidants. J. Lipid Res. 38:1997;2455-2464.